1455 related articles for article (PubMed ID: 27106502)
1. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer.
Ahmad N; Alam MA; Ahmad R; Naqvi AA; Ahmad FJ
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):432-446. PubMed ID: 28503995
[TBL] [Abstract][Full Text] [Related]
3. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
[TBL] [Abstract][Full Text] [Related]
5. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects.
Tahara K; Yamamoto H; Hirashima N; Kawashima Y
Eur J Pharm Biopharm; 2010 Mar; 74(3):421-6. PubMed ID: 20034563
[TBL] [Abstract][Full Text] [Related]
7. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine.
Grabovac V; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2007 Jul; 33(7):767-74. PubMed ID: 17654025
[TBL] [Abstract][Full Text] [Related]
8. Transient aggregation of chitosan-modified poly(d,l-lactic-co-glycolic) acid nanoparticles in the blood stream and improved lung targeting efficiency.
Lee SY; Jung E; Park JH; Park JW; Shim CK; Kim DD; Yoon IS; Cho HJ
J Colloid Interface Sci; 2016 Oct; 480():102-108. PubMed ID: 27421112
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.
Zhao K; Zhang Y; Zhang X; Shi C; Wang X; Wang X; Jin Z; Cui S
Int J Nanomedicine; 2014; 9():4609-19. PubMed ID: 25356070
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
12. PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers.
Jiang G; Jia H; Qiu J; Mo Z; Wen Y; Zhang Y; Wen Y; Xie Q; Ban J; Lu Z; Chen Y; Wu H; Ni Q; Chen F; Lu J; Wang Z; Li H; Chen J
Int J Nanomedicine; 2020; 15():9373-9387. PubMed ID: 33262593
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation.
Pandit J; Sultana Y; Aqil M
Artif Cells Nanomed Biotechnol; 2017 Nov; 45(7):1397-1407. PubMed ID: 27855494
[TBL] [Abstract][Full Text] [Related]
15. Surface-modified PLGA nanoparticles with chitosan for oral delivery of tolbutamide.
Shi Y; Xue J; Jia L; Du Q; Niu J; Zhang D
Colloids Surf B Biointerfaces; 2018 Jan; 161():67-72. PubMed ID: 29040836
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
17. Intracellular delivery of cysteine protease inhibitor cystatin by polymeric nanoparticles.
Cegnar M; Kos J; Kristl J
J Nanosci Nanotechnol; 2006; 6(9-10):3087-94. PubMed ID: 17048522
[TBL] [Abstract][Full Text] [Related]
18. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
19. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
